Log in or register to see all Alerts
New HTA Decisions in England
September 2020
Drug name
(glasdegib)
Company
Pfizer
Decision date
//
Therapeutic area
Blood and immune system conditions
Therapeutic sub area
Blood and bone marrow cancers
Decision
Not recommended
Indication
With chemotherapy for untreated acute myeloid leukaemia (terminated appraisal).
Decision Detail
This was a terminated appraisal.
Summary
NICE was unable to make a recommendation on glasdegib with chemotherapy for untreated acute myeloid leukaemia because the company did not provide an evidence submission. NICE will review this decision if the company decides to make a submission. The company has confirmed that it does not intend to make a submission for the appraisal because the technology is unlikely to be a cost-effective use of NHS resources.